New at Oracle
New Assurances Accompany Oracle Validated Integrations
Oracle’s Applications Unlimited customers need third-party software solutions with effective integration with Oracle E-Business Suite, and Oracle’s PeopleSoft, JD Edwards, and Siebel customer relationship management (CRM) applications. Fortunately, the Oracle Validated Integration program connects customers to partners with confirmed Oracle application integration experience.
Each Oracle Validated Integration has undergone rigorous testing to ensure it is functionally and technically sound, uses reliable standards for integrations, and performs as documented. This eases the upgrade process, speeds implementation, reduces costs, and increases satisfaction.
The significant installed base of Oracle’s Applications Unlimited product lines—Oracle E-Business Suite and PeopleSoft Enterprise, Siebel CRM, JD Edwards EnterpriseOne, and JD Edwards World—stands to benefit with a reliable way to extend investments in these applications.
“Customers today are challenged with fully integrating new and existing applications, to maximize their IT investments and drive further business value,” says Judson Althoff, senior vice president, Worldwide Alliances and Channels, at Oracle. “By developing SOA-based integrations, partners offer solutions best suited for Oracle Applications, with rapid, low-cost implementations and easier upgrades for their customers. Oracle Validated Integrations can provide our mutual customers the peace of mind that the application integration has been put through stringent testing and validation and should perform properly in real-world implementations.”
Currently, Oracle has validated 500 partner integrations—and customers are reaping the benefits. “In today’s environment, it is all about how we help our customers deliver superior customer care at the lowest cost,” says Chris McGugan, vice president of product management and marketing at Avaya. “Our Oracle Validated Integration with Siebel CRM helps Avaya Interaction Center customers realize faster time to market of higher-quality services and support, ultimately improving their business bottom line.”
Oracle Health Sciences Industry Suite Gains Drug Safety Features with Relsys
Drug safety is essential in the biotech and pharmaceutical sectors, but these days it extends beyond the practices used during clinical development. Companies also are responsible for monitoring safety once a drug is on the market and available to patients. Oracle’s 2009 acquisition of Relsys and its suite of safety and risk management solutions has expanded the Oracle Health Sciences products to provide comprehensive support for the end-to-end drug safety process.
Oracle Health Sciences now encompasses Oracle’s Argus safety applications, including Oracle Argus Safety, Oracle Argus Insight, and Oracle Argus Perceptive, among others. With the expanded capabilities, customers can identify safety risks earlier in the development cycle, provide greater transparency into safety reporting, and allow companies to better perform postmarket surveillance through an integrated and proactive risk management strategy.
Market demands around drug safety, risk management, and analytics are growing at a rapid pace, especially as healthcare payers, providers, the pharmaceutical industry, and regulators are becoming increasingly linked.
“An enterprise solution such as Oracle Argus Safety that is highly integrated and supports collaboration is a critical necessity,” says John Loucks, vice president of global sales for Oracle Health Sciences.
Firms that implement Oracle Argus Safety also can expect to see a reduction in total cost of ownership because it helps organizations align their business operations and improve efficiencies. Many companies struggle with data scattered throughout the enterprise. With an integrated system, data replication is eliminated, making it easier to perform accurate data analysis.
“It is one thing to collect data. With an integrated application like Oracle Argus Safety, customers can easily analyze data and identify trends that they may not have otherwise known about,” says Loucks. “They can mine the data for drug interactions that may have been otherwise difficult to uncover.”